JP2010189333A - POWDER COMPOSITION, TABLET, METHOD FOR PREVENTING BROWNING OF gamma-AMINOBUTYRIC ACID AND BROWNING INHIBITOR - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a powder composition suppressing browning occurring during preservation of a γ-aminobutyric acid. <P>SOLUTION: The powder composition comprises a γ-aminobutyric acid and a hyaluronic acid and/or its salt and has an average particle diameter of 5-500 μm. <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

  The present invention relates to a powdery composition, a tablet containing the same, a method for preventing browning of γ-aminobutyric acid, and a browning inhibitor. More specifically, the present invention relates to a powdery composition that prevents browning of γ-aminobutyric acid and is excellent in long-term storage stability, and a tablet containing the same.

  γ-Aminobutyric acid (GABA) is a kind of non-protein constituent amino acid and widely exists in nature. It is known that it is biosynthesized from glutamic acid in vivo and works as a neurotransmitter in the human brain. In addition, γ-aminobutyric acid is used in foods and pharmaceuticals because it exhibits physiological functions such as a brain function improving action, a blood pressure lowering action, and a relaxing action when taken orally.

On the other hand, powdered γ-aminobutyric acid has a high hygroscopic property, and usually an excipient is added to improve storage stability. Lactose and dextrins are widely used as excipients added to suppress the hygroscopicity of the above-mentioned γ-aminobutyric acid. However, when these are used as excipients, depending on the storage conditions, the amino group of γ-aminobutyric acid and the carbonyl group of the sugar may undergo a Maillard reaction and the powder may turn brown.

  Therefore, as a technique for preventing browning of the powder containing γ-aminobutyric acid, a reduced starch degradation product containing 70% or more of cyclic dextrin and / or sugar having a polymerization degree of 3 or more is used as an excipient. Is known (Patent Document 1). Patent Document 1 discloses a composition containing a high amount of powdery γ-aminobutyric acid, which has excellent storage stability by use of the above-mentioned excipients, and has suppressed browning even when stored at a high temperature. It is stated that it can be provided.

  By using the excipient of Patent Document 1, it is possible to surely prevent the browning of the powder containing γ-aminobutyric acid. However, if the physiologically active substance, not the excipient, has a similar browning preventing effect, γ -When an aminobutyric acid-containing powder is orally ingested, it is expected that physiological functions are enhanced and a synergistic effect is obtained.

On the other hand, hyaluronic acid is a mucopolysaccharide present in living bodies, particularly subcutaneous tissues, and has been widely used as a raw material for cosmetics as hyaluronic acid or a salt thereof due to its high moisturizing function. In addition, by ingesting hyaluronic acid or a salt thereof, the effect of improving the moisture retention, elasticity and flexibility of the skin (Patent Document 2), the effect of improving constipation (Patent Document 3), the effect of alleviating autoimmune diseases It is known to have physiological effects such as (Patent Document 4). However, no effect was known about the effect of preventing browning of γ-aminobutyric acid.
JP 2008-150350 A JP 2002-356432 A JP 2000-060487 A JP 2008-266171 A

  An object of the present invention is to provide a powdery composition that improves the storage stability of a powdery composition containing γ-aminobutyric acid and does not easily brown during storage.

In order to achieve the above object, the present inventors have conducted extensive research on the prevention of browning of a powdery composition containing γ-aminobutyric acid. As a result, γ-aminobutyric acid and hyaluronic acid and / or a salt thereof are mixed. Then, unexpectedly, it discovered that browning of the powdery composition containing (gamma) -aminobutyric acid could be prevented, and came to complete this invention.
That is, the present invention
(1) A powdery composition containing γ-aminobutyric acid, containing hyaluronic acid and / or a salt thereof, and having an average particle size of 5 to 500 μm,
(2) The powdery composition of (1), wherein the molecular weight of hyaluronic acid and / or a salt thereof is 1 to 2 million,
(3) A tablet containing the powdery composition of (1) or (2),
(4) a capsule containing the powdery composition of (1) or (2),
(5) A method for preventing browning of a powdery composition containing γ-aminobutyric acid, which contains γ-aminobutyric acid and hyaluronic acid and / or a salt thereof to prepare a powdery composition,
(6) A browning inhibitor for γ-aminobutyric acid, characterized by containing hyaluronic acid and / or a salt thereof,
It is.

  Since the powdery composition of the present invention can prevent browning of γ-aminobutyric acid by mixing hyaluronic acid and / or a salt thereof, the quality of γ-aminobutyric acid can be kept good for a long period of time.

  The present invention will be described below. In the present invention, “%” means “mass%” and “part” means “part by mass”.

  The powdery composition of the present invention is characterized by containing γ-aminobutyric acid.

  γ-aminobutyric acid is generally called GABA and refers to one kind of non-protein amino acid widely distributed in nature. It is also contained in tea, vegetables, cereals and the like as ingredients of food.

The γ-aminobutyric acid used in the powdery composition according to the present embodiment is not particularly limited, but γ-aminobutyric acid extracted from vegetables, fruits, cereals and the like, and γ- produced by a fermentation method. Aminobutyric acid, γ-aminobutyric acid produced from organic synthesis can be used. Among them, a fermentation method using lactic acid bacteria is preferable because γ-aminobutyric acid can be obtained in a large amount and at low cost. Examples of the production method by the fermentation method include the following methods. For example, a pre-culture solution such as lactic acid bacteria (Lactobacillus brevis (IFO12005), Lactobacillus hillgardi K-3 strain (FERM P-18422)) is added to a culture solution containing soda glutamate, glucose, baker's yeast extract, etc. Incubate at 20 to 30 ° C. for 1 to 3 days, and heat and sterilize this culture solution to obtain a filtrate by filtration using a filter aid such as diatomaceous earth, cellulose, or activated carbon. In addition, when Lactobacillus hilgardy K-3 strain (FERM P-18422) is used as a lactic acid bacterium, the concentration of γ-aminobutyric acid is particularly effective by adding 5% or more of sodium glutamate to the culture solution. The content of γ-aminobutyric acid in the culture broth is about 5% by mass, and when converted to solid content, γ-aminobutyric acid is about 5%. In addition, by setting the pH of the culture solution to 4.5 to 5.5, the growth of lactic acid bacteria is particularly effectively promoted, and the content of γ-aminobutyric acid in the culture solution can be increased. The above filtrate can be used for the powdery composition of the present invention by appropriately concentrating by reduced pressure concentration, vacuum concentration, etc., or as it is or by further drying by spray drying, freeze drying, etc. Furthermore, γ -In order to increase the content of aminobutyric acid, purification by liquid chromatography or the like can also be performed.

  The method for detecting γ-aminobutyric acid in the powdered composition or tablet according to the present embodiment is not particularly limited. For example, it is separated by high performance chromatography (HPLC) using an ion exchange column, and ortho After derivatization with phthalaldehyde (OPA), after derivatization with a fluorescence detector, after separation by high-speed chromatography, after derivatization with post-column with ninhydrin, detection with a UV-visible detector The method of doing is mentioned.

  The powdery composition of the present invention is characterized by containing hyaluronic acid and / or a salt thereof.

  The “hyaluronic acid” in the present invention refers to a polysaccharide having one or more repeating structural units composed of disaccharides of glucuronic acid and N-acetylglucosamine. The “hyaluronic acid salt” is not particularly limited, but is preferably a food or pharmaceutically acceptable salt, for example, sodium salt, potassium salt, calcium salt, zinc salt, magnesium salt, ammonium salt, etc. Is mentioned.

  The average molecular weight of hyaluronic acid and / or a salt thereof used in the powdery composition of the present invention is preferably 1 to 2 million, more preferably 5 to 1.6 million, and still more preferably 10 to 1.2 million. When the average molecular weight of hyaluronic acid and / or a salt thereof is less than 10,000, it is difficult to obtain the effects of the present invention, which is not preferable. On the other hand, when the average molecular weight of hyaluronic acid and / or its salt exceeds 2 million, it may be difficult to process into food.

  The average molecular weight of the purified hyaluronic acid used in the present invention is defined as a value determined by the following method.

About 0.05 g of purified hyaluronic acid is accurately weighed and dissolved in 0.2 mol / L sodium chloride solution to make exactly 100 mL, and 8 mL, 12 mL and 16 mL of this solution are accurately weighed, and 0.2 mol each. / L concentration of sodium chloride solution is added to make exactly 20 mL as a sample solution. This sample solution and 0.2 mol / L sodium chloride solution were 30.0 ± 0.1 ° C. according to the viscosity measurement method (first method capillary viscometry method) of the Japanese Pharmacopoeia (14th revision) general test method. The specific viscosity is measured by (Equation (1)), and the reduced viscosity at each concentration is calculated (Equation (2)). A graph is drawn with the reduced viscosity on the vertical axis and the concentration (g / 100 mL) of the product converted to dry matter on the horizontal axis, and the intrinsic viscosity is determined from the intersection of the straight line connecting the points and the vertical axis. Substituting the intrinsic viscosity obtained here into Laurent's formula (formula (3)), the average molecular weight is calculated (TC
Laurent, M. Ryan, A. Pietruszkiewicz,: BBA, 42, 476-485 (1960)).

Hyaluronic acid and / or a salt thereof may be extracted from natural products such as animals (for example, biological tissues such as chicken crown, umbilical cord, skin, joint fluid, etc.), or obtained by culturing microorganisms or animal cells. And the like (for example, fermentation using a bacterium belonging to the genus Streptococcus, etc.), or those synthesized chemically or enzymatically can be used.

Commercially available products can be used as the hyaluronic acid and / or salt thereof used in the powdery composition according to the present embodiment, and for example, it can also be produced according to the following production methods 1 and 2.

1.1. Production method 1 (extraction from chicken crown) The chicken crown is heated. The heat treatment method, the heating temperature, and the time are not particularly limited as long as the protein in the chicken crown is denatured or the enzyme is deactivated. When a heating method using hot water is adopted, 60 to The raw material is preferably immersed in hot water at 100 ° C.

Next, paste the heat-treated chicken crown, add acid agent such as hydrochloric acid or sulfuric acid, or add alkali agent such as sodium hydroxide or potassium hydroxide to reduce the molecular weight of hyaluronic acid by acid treatment or alkali treatment. The average molecular weight of hyaluronic acid is adjusted. As the adjustment method, the concentration of the acid agent or alkali agent, the amount added, and the treatment time may be appropriately combined so that the hyaluronic acid after treatment has a desired molecular weight. It is preferable because the molecular weight can be easily controlled.

Next, a protease is added to the raw material whose molecular weight has been adjusted, and protease treatment is performed. Any proteolytic enzyme can be used as long as it is commercially available, and examples thereof include pepsin, trypsin, papain, promeline and the like.

Finally, hyaluronic acid is fractionated from the obtained protease-treated product to obtain crude hyaluronic acid, and then the hyaluronic acid is purified to obtain hyaluronic acid having a purity of 90% or more.

Here, the fractionation and purification of hyaluronic acid can be performed according to a conventional method. For example, first, the protease-treated raw material is filtered to remove solids to obtain a filtrate containing crude hyaluronic acid. Prior to filtration, activated carbon may be added to the protease-treated product for the purpose of deodorization / decolorization or removal of some protein degradation products. And after melt | dissolving salt in the obtained filtrate, ethanol is added and hyaluronic acid is precipitated, and a deposit is fractionated. Thereafter, hydrous ethanol having an ethanol concentration of about 80 to 95% by volume is added to the precipitate, washed with a homogenizer, and the precipitate is collected. The hyaluronic acid of Production Example 1 can be obtained by repeating this washing with hydrous ethanol about 2 to 10 times and drying the collected precipitate.

1.2. Production method 2 (microbe fermentation method)
Activated carbon is added to the culture solution of the hyaluronic acid producing Streptococcus genus (Streptococcus Zoopidemicus), followed by deodorization and decolorization treatment, followed by filtration treatment. Sodium chloride is dissolved in the obtained filtrate, ethanol is added to precipitate hyaluronic acid, and the precipitate is collected. Thereafter, hydrous ethanol having an ethanol concentration of about 80 to 95% by volume is added to the precipitate, washed with a homogenizer, and the precipitate is collected. The hyaluronic acid of Production Example 2 can be obtained by repeating this washing with hydrous ethanol about 2 to 10 times and drying the collected precipitate.

In addition, the purity of the hyaluronic acid used in the present invention may be a level that can be used in food, preferably 90% or more, more preferably 95% or more. This purity is defined as a value obtained by removing impurities other than hyaluronic acid from 100% in terms of dry matter. Here, examples of the impurities include protein degradation products, fat (crude fat), chondroitin sulfate, and the like. Specifically, the purity of hyaluronic acid using chicken crown as a raw material can be obtained by the following formula (4).

  In Formula 4, the protein degradation product (%) is a value obtained by the Lowry method, and the crude fat (%) is a new food analysis method (published by Korin Co., Ltd.) “Chapter 1 General components and related components, 1- “4 lipids, 1-4-2 ether extraction method”, and chondroitin sulfate (%) is a value obtained by the method described below.

  First, hyaluronic acid is dried, 50 mg of it is accurately weighed, and purified water is added to dissolve it. Make exactly 100 mL to make a test solution, take 4 mL of the test solution in a test tube, and add 1 mL of 0.5 mol / L sulfuric acid. Then, 0.2 mL of 0.04 mol / L cetyltrimethylammonium bromide was added to the solution obtained by heating in a water bath for 10 minutes and then cooling, and the mixture was allowed to stand at room temperature for 1 hour. Absorbance at a length of 10 mm and a wavelength of 660 nm is measured.

  Next, the obtained absorbance data is applied to a calibration curve for chondroitin sulfate to determine the amount (%) of chondroitin sulfate in purified hyaluronic acid. Here, the calibration curve is obtained by drying (depressurization, phosphorus pentoxide, 60 ° C., 5 hours) of chondroitin sulfate A sodium salt (SG (Special Grade), manufactured by Seikagaku Corporation) derived from whale cartilage. Precisely weigh, dissolve in purified water, and prepare solutions containing 10 μg, 20 μg, 30 μg, and 40 μg of chondroitin sulfate A sodium salt in 1 mL, respectively. For each 4 mL of solution, 1 mL of 0.5 mL / L sulfuric acid Then, 0.2 mL of 0.04 mol / L cetyltrimethylammonium bromide was added and mixed. After standing at room temperature for 1 hour, the absorbance was measured in the same manner. It was prepared by plotting the corresponding chondroitin sulfate A sodium salt solution (μg / mL) on the horizontal axis.

  The average particle size of the powdery composition of the present invention is preferably 5 to 500 μm. When the average particle size of the powder composition is below the above range, γ-aminobutyric acid contained in the powder composition is very easily browned during storage, and is browned by adding hyaluronic acid and / or a salt thereof. The prevention effect may not work sufficiently. In addition, when the average particle size of the powdery composition is larger than the above range, it is difficult to cause browning derived from γ-aminobutyric acid contained in the powdery composition, and thus it is not necessary to use the effect of the present invention. is there. Examples of the method for measuring the average particle diameter include generally known laser diffraction measurement methods and dynamic light scattering measurement methods.

  In the powdered composition of the present invention, the content ratio of hyaluronic acid and / or a salt thereof to 1 part of γ-aminobutyric acid is preferably 0.01 parts or more, more preferably 0.1 parts or more. . By containing γ-aminobutyric acid and hyaluronic acid or a salt thereof in the powder composition in the above ratio, browning of γ-aminobutyric acid can be prevented. In the case where the content ratio of hyaluronic acid and / or salt thereof to 1 part of γ-aminobutyric acid is more than 10 parts, even if the content of hyaluronic acid and / or salt thereof is further increased, γ-aminobutyric acid There is no significant effect on the browning prevention effect, so it is not economical.

  The tablet according to the present embodiment refers to a tablet-like food or medicine containing γ-aminobutyric acid, hyaluronic acid and / or a salt thereof, which is a powdery composition. By using the powdery composition of the present invention, a tablet that hardly undergoes browning during storage can be obtained.

The capsule according to the present embodiment refers to a capsule-like food or medicine containing γ-aminobutyric acid, hyaluronic acid and / or a salt thereof, which is a powdery composition. By using the powdery composition of the present invention, a capsule that hardly undergoes browning during storage can be obtained.

  If the manufacturing method of the powdery composition of this invention can obtain the powdery composition with an average particle diameter of 5-500 micrometers containing (gamma) -aminobutyric acid and hyaluronic acid and / or its salt especially, It is not limited. For example, a method in which a solution containing γ-aminobutyric acid and a solution containing hyaluronic acid and / or a salt thereof are mixed, dried by spray drying, freeze drying, etc., and then pulverized as necessary In addition, there may be mentioned a method in which a powder containing γ-aminobutyric acid and a powder containing hyaluronic acid and / or a salt thereof are mixed to obtain a powdery composition having an average particle size of 5 to 500 μm.

  Next, the present invention will be described in more detail based on examples, comparative examples, and test examples. The present invention is not limited to these.

[Preparation Example 1]
After sterilizing 50 L of fermentation raw material (pH 5.0) containing 100 g / L of sodium glutamate, 2 g / L of glucose, 5 g / L of yeast extract, and 0.5 g / L of glycerin fatty acid ester at 90 ° C. for 10 minutes. Inoculated with 50 mL of kimchi-derived lactic acid bacteria (Lactobacillus hilgardy K-3 strain (FERM P-18422)) and cultured at 30 ° C. for 3 days. After sterilizing this fermentation broth at 90 ° C. for 10 minutes, adding a filter aid, filtering, passing through a column of Diaion SK1B (H type) (manufactured by Mitsubishi Chemical Corporation), adsorbing γ-aminobutyric acid, After washing with water and eluting with 0.5N ammonia water, each γ-aminobutyric acid was collected. The collected fractions were concentrated, adjusted to pH 6.2, ethanol was added, and the mixture was stored under cooling to obtain γ-aminobutyric acid crystals having a purity of 98% or more. The crystals were pulverized with a pulverizer (manufactured by Hosokawa Micron Corporation), and the average particle size was adjusted to 130 μm. In the following, the average particle size of the powder was measured by dispersing the powder in ethanol and using SALD-2000A (manufactured by Shimadzu Corporation).

[Test Example 1]
In this test example, the difference by the presence or absence of hyaluronic acid and / or its salt was investigated about the browning prevention effect of the powdery composition of this invention containing (gamma) -aminobutyric acid and hyaluronic acid and / or its salt. In addition, the hyaluronic acid and / or salt thereof, and dextrin contained therein had an average particle diameter of 100 to 200 μm.

  The component (powder composition) shown in Table 1 was prepared, and powder mixing was performed at the ratio (parts by mass) shown in Table 1. 1.0 g of the powdery composition of each formulation was taken and placed in a weighing bottle and stored in a constant temperature and humidity chamber (manufactured by Tokyo Rika Kikai Co., Ltd.) at 40 ° C. and 75% humidity. The change in color tone was visually confirmed before and after 20 minutes, 40 minutes and 60 minutes after putting in the thermo-hygrostat. The results are shown in Table 2.

  As a result of visually confirming the color tone, in the dextrin of Formulation Example 4, the effect of preventing browning was hardly observed. On the other hand, the browning prevention effect was confirmed in the powdery compositions of Formulation Examples 1 to 3 containing hyaluronic acid and / or a salt thereof. As mentioned above, it turns out that hyaluronic acid and / or its salt are excellent in the browning prevention effect of the powdery composition containing (gamma) -aminobutyric acid.

[Formulation Example 5]
Fermentation was carried out in the same manner as in Preparation Example 1 and passed through an ion exchange resin column to collect a γ-aminobutyric acid fraction. 2 kg of hyaluronic acid (prepared by production method 2) having an average molecular weight of 200,000 was dissolved in this, and then spray-dried to obtain a powdery composition of Formulation Example 5. The average particle diameter of this powdery composition was 35 μm, and the content of hyaluronic acid relative to γ-aminobutyric acid was 0.8.

[Composition Example 6]
Fermentation was performed in the same manner as in Preparation Example 1 and passed through an ion exchange resin column to collect a γ-aminobutyric acid fraction. 2 kg of hyaluronic acid having an average molecular weight of 8,000 (prepared by the production method 2) was dissolved in this, and then spray-dried to obtain a powdery composition of Formulation Example 6. The average particle diameter of this powdery composition was 28 μm, and the content of hyaluronic acid relative to γ-aminobutyric acid was 0.8.

[Test Example 2]
In this test example, in order to investigate the difference due to the average molecular weight of hyaluronic acid and / or salt thereof, the browning prevention effect of the powdery composition containing γ-aminobutyric acid of the present invention and hyaluronic acid and / or salt thereof, Evaluation by a color difference meter was performed.

  0.7 g of the mixture of [Composition Example 5] and [Composition Example 6] was put in a weighing bottle and stored in a constant temperature and humidity chamber (manufactured by Tokyo Rika Kikai Co., Ltd.) at 40 ° C. and 75% humidity. A change in color tone before and 60 minutes after putting in a thermo-hygrostat was confirmed with a color difference meter (colorimetric color difference meter ZE2000, manufactured by Nippon Denshoku Industries Co., Ltd.). The results of measuring the color tone with a color difference meter are shown in Table 3.

  From the results of Table 3, as a result of measurement with a color difference meter, it can be seen that almost no change in color tone before and after storage was observed in Formulation Example 5. On the other hand, in Formulation Example 6, a change in color tone before and after storage was confirmed. Therefore, it can be seen that the average molecular weight of hyaluronic acid and / or a salt thereof is 10,000 or more is more excellent in the browning prevention effect of γ-aminobutyric acid.

[Preparation Example 2]
Fermentation was carried out in the same manner as in Preparation Example 1 to obtain γ-aminobutyric acid crystals having a purity of 98% or more. This crystal was pulverized while adjusting the particle size with a pulverizer (manufactured by Hosokawa Micron Corporation) to obtain powdery γ-aminobutyric acid having an average particle size of 3 μm, 19 μm, 367 μm, and 649 μm.

[Test Example 3]
In this test example, the difference by the average particle diameter of a powdery composition was investigated about the browning prevention effect of the powdery composition containing (gamma) -aminobutyric acid of this invention, hyaluronic acid, and / or its salt. The contained hyaluronic acid (average molecular weight of 200,000) was used having an average particle size of 4 to 707 μm.

  The components (powder composition) shown in Table 4 were prepared, and powder mixing was performed at the ratio shown in Table 4. 1.0 g of the powdery composition of each formulation was taken and placed in a weighing bottle and stored in a constant temperature and humidity chamber (manufactured by Tokyo Rika Kikai Co., Ltd.) at 40 ° C. and 75% humidity. The change in color tone was visually confirmed before and after 20 minutes, 40 minutes and 60 minutes after putting in the thermo-hygrostat. The results are shown in Table 6. Moreover, as shown in Table 5, as Reference Examples 2 to 5, the γ-aminobutyric acid powder was stored alone, and the change in color tone was confirmed visually. The results are shown in Table 7.

  From the results of Table 6 and Table 7, in the case of Formulation Example 7 and Reference Example 2 in which the average particle size of the powdery composition is less than 5 μm, the degree of browning of γ-aminobutyric acid is very large, and thus hyaluronic acid and / or It can be seen that the effect of preventing browning is insufficient even by the addition of the salt. On the other hand, in Formulation Examples 8 and 9 and Reference Examples 3 and 4 where the average particle size of the powdery composition is 5 to 500 μm, browning during storage is effectively prevented by the addition of hyaluronic acid and / or a salt thereof. ing. Moreover, in the case of the blending example 10 and the reference example 5 whose average particle diameter of a powdery composition is over 500 micrometers, it turns out that the browning of (gamma) -aminobutyric acid during a preservation | save does not occur easily.

[Test Example 4]
In this test example, the difference due to the content of hyaluronic acid and / or a salt thereof was investigated for the browning prevention effect of the powdery composition of the present invention containing γ-aminobutyric acid and hyaluronic acid and / or a salt thereof. .

  The components (powder composition) shown in Table 8 were prepared, and powder mixing was performed at the ratio (parts by mass) shown in Table 8. 1.0 g of the powdery composition of each formulation was taken and placed in a weighing bottle and stored in a constant temperature and humidity chamber (manufactured by Tokyo Rika Kikai Co., Ltd.) at 40 ° C. and 75% humidity. The change in color tone was visually confirmed before and after 20 minutes, 40 minutes and 60 minutes after putting in the thermo-hygrostat. The results are shown in Table 9. The sodium hyaluronate contained (average molecular weight 30,000) was used having an average particle size of 182 μm.

  From the results of Table 9, the content of hyaluronic acid and / or salt thereof with respect to 1 part of γ-aminobutyric acid in the powdery composition is preferably 0.01 parts or more, more preferably 0.1 parts or more. It can be seen that it is. On the other hand, when the content of hyaluronic acid with respect to 1 part of γ-aminobutyric acid is 10 parts or more (Formulation Examples 13 and 14), the effect is sufficiently excellent in preventing browning, and even if the content is increased, the effect is greatly changed. I understand that there is no.

[Formulation Example 15]
Using the powdery composition of Formulation Example 5, tablets were prepared with the following formulation so that one tablet would be 250 mg. When this tablet was filled in a glass bottle with a lid and stored at 25 ° C. (humidity 60%), no browning was observed even during storage for one year, and good quality was maintained.

<Combination ratio>
15% of powdered composition of Formulation Example 5
Lactose 50%
20% crystalline cellulose
Corn starch 10%
Glycerin fatty acid ester 5%
――――――――――――――――――――――――――
Total 100%

[Composition Example 16]
Using the powdery composition of Formulation Example 2, soft capsules were produced with a soft capsule filling machine using gelatin as an encapsulant so that one tablet would be 300 mg in the following formulation. When this capsule was filled in a glass bottle with a lid and stored at 25 ° C. (humidity 60%), browning was not observed even during storage for one year, and good quality was maintained.

<Combination ratio>
10% of powdery composition of Formulation Example 2
Vitamin E 15%
Soy lecithin 7%
Safflower oil 55%
Vitamin C 8%
Glycerin fatty acid ester 2%
Beeswax 3%
――――――――――――――――――――――――――
Total 100%

Since the powdery composition of the present invention prevents the browning of γ-aminobutyric acid during storage, it can provide a γ-aminobutyric acid-containing powdered composition with good quality during distribution and after storage. Moreover, it is possible to mix | blend and use the powdery composition of this invention for a foodstuff or a pharmaceutical.

Claims (6)

A powdery composition containing γ-aminobutyric acid, containing hyaluronic acid and / or a salt thereof, and having an average particle diameter of 5 to 500 μm. The powdery composition of Claim 1 whose molecular weight of hyaluronic acid and / or its salt is 1-2 million. The tablet containing the powdery composition of Claim 1 or 2. The capsule containing the powdery composition of Claim 1 or 2. A method for preventing browning of a powdery composition containing γ-aminobutyric acid, which comprises adding γ-aminobutyric acid and hyaluronic acid and / or a salt thereof to prepare a powdery composition. An anti-browning agent for γ-aminobutyric acid, comprising hyaluronic acid and / or a salt thereof.